Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies

被引:10
|
作者
Arrieta, Oscar [1 ]
Lara-Mejia, Luis [1 ]
Bautista-Gonzalez, Elysse [2 ]
Heredia, David [1 ]
Turcott, Jenny G. [1 ]
Barron, Feliciano [1 ]
Ramos-Ramirez, Maritza [1 ]
Cabrera-Miranda, Luis [1 ]
Salinas Padilla, Miguel Angel [1 ]
Aguerrebere, Mercedes [3 ]
Cardona, Andres F. [4 ]
Rolfo, Christian [5 ,6 ]
Arroyo-Hernandez, Marisol [1 ]
Soto-Perez-de-Celis, Enrique [7 ]
Baez-Saldana, Renata [8 ]
机构
[1] Inst Nacl Cancerol INCan, Thorac Oncol Unit, Av San Fernando 22,Secc 16, Mexico City 14080, DF, Mexico
[2] UCL, Inst Epidemiol & Publ Hlth, London, England
[3] Inst Nacl Psiquiatria, Mexico City, DF, Mexico
[4] Clin Country, Clin & Translat Oncol Grp, Bogota, Colombia
[5] Mt Sinai Med Syst, Ctr Thorac Oncol, Tisch Canc Inst, New York, NY USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Inst Nacl Ciencias Med & Nutr & Salvador Zubiran, Mexico City, DF, Mexico
[8] Inst Nacl Enfermedades Respiratorias INER, Mexico City, DF, Mexico
来源
ONCOLOGIST | 2021年 / 26卷 / 12期
关键词
Pandemic; Lung cancer; Coronavirus disease 2019; Severe acute respiratory syndrome coronavirus 2; Thoracic neoplasms; CORONAVIRUS DISEASE 2019; DEPRESSION ANXIETY; PSYCHOMETRIC PROPERTIES; STRESS SCALE-21; CARE; DELAYS;
D O I
10.1002/onco.13962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Accumulated evidence indicates that patients with lung cancer are a vulnerable population throughout the pandemic. Limited information is available in Latin America regarding the impact of the pandemic on medical care. The goal of this study was to describe the clinical and social effect of COVID-19 on patients with thoracic cancer and to ascertain outcomes in those with a confirmed diagnosis. Materials and Methods This cohort study included patients with thoracic neoplasms within a single institution between March 1, 2020, and February 28, 2021. All variables of interest were extracted from electronic medical records. During this period, the Depression Anxiety and Stress Scale 21 (DASS-2) was applied to evaluate and identify more common psychological disorders. Results The mean age for the total cohort (n = 548) was 61.5 +/- 12.9 years; non-small cell lung cancer was the most frequent neoplasm (86.9%), advanced stages predominated (80%), and most patients were under active therapy (82.8%). Any change in treatment was reported in 23.9% of patients, of which 78.6% were due to the COVID-19 pandemic. Treatment delays (>= 7 days) were the most frequent modifications in 41.9% of cases, followed by treatment suspension at 37.4%. Patients without treatment changes had a more prolonged progression-free survival and overall survival (hazard ratio [HR] 0.21, p < .001 and HR 0.28, p < .001, respectively). The mean DASS-21 score was 10.45 in 144 evaluated patients, with women being more affected than men (11.41 vs. 9.08, p < .001). Anxiety was reported in 30.5% of cases, followed by depression and distress in equal proportions (18%). Depressed and stressed patients had higher odds of experiencing delays in treatment than patients without depression (odds ratio [OR] 4.5, 95% confidence interval [CI] 1.53-13.23, p = .006 and OR 3.18, 95% CI 1.2-10.06, p = .006, respectively). Conclusion Treatment adjustments in patients with thoracic malignancies often occurred to avoid COVID-19 contagion with detrimental effects on survival. Psychological disorders could have a role in adherence to the original treatment regimen. Implications for Practice The pandemic has placed an enormous strain on health care systems globally. Patients with thoracic cancers represent a vulnerable population, with increased morbidity and mortality rates. In Mexico, treatment modifications were common during the pandemic, and those who experienced delays had worse survival outcomes. Most treatment modifications were related to a patient decision rather than a lockdown of health care facilities in which mental health impairment plays an essential role. Moreover, the high case fatality rate highlights the importance of improving medical care access. Likewise, to develop strategies facing future threats that may compromise health care systems in non-developed countries.
引用
收藏
页码:1035 / 1043
页数:9
相关论文
共 50 条
  • [41] Impact of the COVID-19 pandemic on clinical trials with drugs
    Hasford, Joerg
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (11) : 1373 - 1375
  • [42] Impact of the COVID-19 Pandemic on Cancer Clinical Trials
    Boughey, Judy C.
    Snyder, Rebecca A.
    Kantor, Olga
    Zheng, Linda
    Chawla, Akhil
    Nguyen, Toan T.
    Hillman, Shauna L.
    Hahn, Olwen M.
    Mandrekar, Sumithra J.
    Roland, Christina L.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (12) : 7311 - 7316
  • [43] Impact of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials
    Audisio, Katia
    Lia, Hillary
    Robinson, Newell Bryce
    Rahouma, Mohamed
    Soletti Jr, Giovanni
    Cancelli, Gianmarco
    Perezgrovas Olaria, Roberto
    Chadow, David
    Tam, Derrick Y.
    Vervoort, Dominique
    Farkouh, Michael E.
    Bhatt, Deepak L.
    Fremes, Stephen E.
    Gaudino, Mario
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2022, 9 (01)
  • [44] Effect of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic.
    Nimgaonkar, Vivek U.
    Berman, Abigail T.
    Gabriel, Peter
    Kucharczuk, John
    Shulman, Lawrence N.
    Aggarwal, Charu
    Marmarelis, Melina E.
    CLINICAL CANCER RESEARCH, 2020, 27 (06)
  • [45] Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel
    Marcus, Nufar
    Frizinsky, Shirly
    Hagin, David
    Ovadia, Adi
    Hanna, Suhair
    Farkash, Michael
    Maoz-Segal, Ramit
    Agmon-Levin, Nancy
    Broides, Arnon
    Nahum, Amit
    Rosenberg, Elli
    Kuperman, Amir Asher
    Dinur-Schejter, Yael
    Berkun, Yackov
    Toker, Ori
    Goldberg, Shmuel
    Confino-Cohen, Ronit
    Scheuerman, Oded
    Badarneh, Basel
    Epstein-Rigbi, Na'ama
    Etzioni, Amos
    Dalal, Ilan
    Somech, Raz
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [46] Impact of the COVID-19 pandemic first wave on the volume and type of systemic anticancer therapy (SACT) delivered for thoracic malignancies
    Decatris, Marios
    Khan, Nowrina
    Ryan, Philip
    Phillips, Aled
    El-Batrawy, Sherouk
    Kalkat, Maninder
    Bowden, Caitlin
    Hayes, Mark
    Taniere, Philippe
    Thomas, Joy
    Du Rand, Ingrid
    LUNG CANCER, 2022, 165 : S15 - S16
  • [47] Dialogue on Mexican childhoods in the COVID-19 pandemic
    Lugo, Norma Alicia Del Rio
    Losso, Mariela Andrea
    EDUCACAO, 2023, 48
  • [48] COVID-19: Impact of a pandemic
    Lujan Cuestas, Maria
    Laura Minassian, Maria
    REVISTA ARGENTINA DE MICROBIOLOGIA, 2020, 52 (03): : 167 - 168
  • [49] Thoracic transplantation during the COVID-19 pandemic
    Ganapathi, Asvin M.
    Henn, Matthew C.
    Lampert, Brent C.
    Nunley, David R.
    Bumgardner, Ginny
    Mokadam, Nahush A.
    Whitson, Bryan A.
    CLINICAL TRANSPLANTATION, 2022, 36 (04)
  • [50] Impact of COVID-19 pandemic on the care of patients with migraine
    Silva, Cristiana
    Fernandes, Carolina
    Luzeiro, Isabel
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 230 - 230